5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11▼ RSI OverboughtRSI 82.2, above 70, stock may be overbought
Jul 10▼ RSI OverboughtRSI 97.1, above 70, stock may be overbought
About Abrdn Life Sciences Investors
Headquartered within the financial services sector, Abrdn Life Sciences Investors focuses on Asset Management services and products. Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The $600.3M market capitalization puts HQL squarely in small-cap range for its industry. The fund invests in public equity markets across the globe.
Premium feature
News & analytics is part of Premium.
Every headline runs through our finance-grade sentiment engine, so you see the mood of the market on each ticker before you read a single article. Plus the full analyst consensus and target-price upside, refreshed daily.
Per-headline sentiment, scored by a finance-tuned model
See exactly where the price sits versus its 150-day moving average, the live RSI reading, MACD momentum, and volume context, for any ticker, every day.
Abrdn Life Sciences Investors reports $852K in cash and $0 in total debt. The company is burning cash, with free cash flow at -$4.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 41.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from -$103.3M (2022) to $86.4M (2025), reflecting a 184% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Abrdn Life Sciences Investors's trajectory.